Taiwan import license bolsters George Clinical's abilities in Asia-Pacific

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/bedo)
(Image: Getty/bedo)

Related tags: George Clinical, Asia-pacific, Clinical trial, Clinical data, Taiwan, Clinical trial site

George Clinical receives license to import clinical trial supply into Taiwan as the Asia-Pacific region continues to develop as a clinical trial site.

The global contract research organization (CRO), which is based in Sydney with offices in Hong Kong, Beijing, Shanghai and Bengaluru, was granted a license to import drugs into Taiwan on behalf of sponsors for clinical trials.

This license will enable George Clinical to provide import services to small and mid-sized clinical trial clients who do not have an entity in Taiwan, as it would otherwise and previously rely on large individual pharmaceutical companies to import on its behalf.

George Clinical stated that with this license in Taiwan it can now serve as a one-stop-shop provider for sponsors looking to expand into Taiwan for trials. Before this license, George Clinical was only able to provide project and site management to its clients instead of drug management.

Additionally, George Clinical now offers drug importation for renewals and amendments, investigational medicinal product (IMP) stock management, closure and inspection after clinical study report submission, re-labeling, return and destruction.

Taiwan, and the Asia-Pacific region are growing as clinical trial locations. The region has a large and diverse patient population​, CROs like Premier Research and PSI CRO​ have both expanded into Taiwan within the last two years.

Premier Research’s VP and head of Asia Pacific, Ashish Jain, previously told us that economic growth​ in the region and greater patient access to new drugs has led to an amplified demand for clinical trials. PSI CRO’s head of corporate development also told us that the country has become an important contributor to global clinical trials after it opened an office in Taipei in 2017. 

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us


View more